S'abonner

Systematic Review and Meta-Analysis: Attention-Deficit/Hyperactivity Disorder Symptoms in Children With Neurofibromatosis Type 1 - 27/03/25

Doi : 10.1016/j.jaac.2024.09.011 
Yang Hou, PhD a, , Liyan Yu, PhD a, Dan Liu, PhD a, Emma Wilson-Lemoine, PhD b, Xian Wu, PhD c, Julia P. Moreira, BS a, Benjamin F. Mujica, BS a, Elora S. Mukhopadhyay, BS a, Angelena N. Novotney, earning BS a, Jonathan M. Payne, DPsych d
a Florida State University, Tallahassee, Florida, USA 
b King's College London, UK 
c University of Kentucky, Lexington, Kentucky, USA 
d Murdoch Children's Research Institute, Australia and The University of Melbourne, Australia 

Correspondence to Yang Hou, PhD, Department of Behavioral Sciences and Social Medicine, College of Medicine, Florida State University, 1115 West Call Street, Tallahassee, FL 32306-4300.Department of Behavioral Sciences and Social MedicineCollege of MedicineFlorida State University1115 West Call StreetTallahasseeFL32306-4300

Abstract

Objective

This meta-analysis aimed to robustly estimate differences in attention-deficit/hyperactivity disorder (ADHD) symptoms between children and adolescents with and without neurofibromatosis type 1 (NF1).

Method

Systematic literature searches were conducted in Scopus, PsycINFO, Web of Science, PubMed, and ProQuest in September 2022, with a supplemental search conducted in Google Scholar in February 2023. The searches identified 2,153 unique articles. Screening identified 114 academic journal articles that assessed parent/caregiver- or teacher-reported ADHD symptoms for children/adolescents with NF1. Two researchers independently screened articles and extracted data. The primary outcome was group differences in ADHD symptoms between children/adolescents with and without NF1 (Hedges g). Data were analyzed using robust variance estimation and random-effects models.

Results

The meta-analysis included 70 studies (138 effect sizes), involving 3,653 children/adolescents with NF1 (46% female; mean age = 9.69 years, SD = 2.60 years) and 4,895 children/adolescents without NF1 (48% female; mean age = 10.03 years, SD = 3.10 years). According to parent/caregiver reports, children/adolescents with NF1 exhibited more severe inattentive symptoms (g = 1.20; 95% CI = 1.06-1.35), hyperactive/impulsive symptoms (g = 0.85; 95% CI = 0. 68-1.03), and combined ADHD symptoms (g = 1.02; 95% CI = 0.87-1.17) than unaffected controls. Inattentive ADHD symptoms were more elevated than hyperactivity/impulsivity for children/adolescents with NF1. Larger effect sizes for inattention and hyperactivity/impulsivity were associated with older age, lower intelligence quotient (IQ), and parent/caregiver vs teacher reports.

Conclusion

NF1 is a monogenic condition that has strong associations with elevated ADHD symptoms. Findings highlight the importance of early intervention and targeted support for ADHD-related problems in children with NF1.

Plain language summary

Increasing evidence has suggested a higher risk for attention-deficit/hyperactivity disorder (ADHD) in individuals with neurofibromatosis type 1 (NF1). In this study of ADHD symptom severity in youth with NF1, the authors analyzed data from 70 articles. The authors found much more severe ADHD symptoms in children and adolescents with NF1 compared to youth without NF1. Inattentive symptoms were more pronounced in children with NIF who were older or had a lower IQ.

Study preregistration information

Compare the ADHD problems between NF1 and control groups; display_record.php?RecordID=462063.

Le texte complet de cet article est disponible en PDF.

Key words : attention deficit disorder with hyperactivity, neurofibromatosis type 1, child, meta-analysis, systematic review


Plan


 This project was funded by a) the Congressionally Directed Medical Research Programs (CDMRP) through the Neurofibromatosis Research Program (NFRP) under Award Number (W81XWH2110504), United States; b) the Florida State University Faculty Startup Funding, United States; and c) the University of Kentucky Faculty Startup Funding, United States.
 This study was presented as a poster at the Society for Research in Child Development Biennial Meeting; March 23–25, 2023; Salt Lake City, Utah. The study was also presented as a virtual poster at the Children’s Tumor Foundation annual NF conference; June 24–27, 2023; Scottsdale, Arizona.
 This work has been prospectively registered: display_record.php?RecordID=462063.
 Data Sharing: Data collected for the study will not be made available to others. No individual-level data were collected. All study-level data meta-analyzed have been provided in the supplemental document.
 Drs. Hou and Yu served as the statistical experts for this research.
 The authors thank Joel Killam, BS, Lauren Morey, BS, Mary-Mac Chown, BS, Devin Guy, BS, Carson Maun, BS, Denny Oliveira, BS, and Taylor Collins, BS, of Florida State University, for their help with literature search, screening, or data extraction.
 Disclosure: Dr. Hou has received funding from the Children’s Tumor Foundation (CTF-2023-10-002) and Florida State University (2024 SEED Grant Award). Dr. Wilson-Lemoine has received funding from the Economic and Social Research Council, Centre for Society and Mental Health at King’s College London [ES/S012567/1] between 2020 – 2023. Dr. Wu has received funding from the National Institute on Aging P01AG078116, the Alzheimer’s Association/the National Alzheimer’s Coordinating Center (NACC) NIAP24-1276268, and the University of Kentucky Center for Clinical and Translational Science (CCTS) DREAM Scholar Program. Dr. Payne has received funding from a Murdoch Children’s Research Institute Clinician Scientist Fellowship. Drs. Yu and Liu, Ms. Moreira, Mr. Mujica, and Mss. Mukhopadhyay and Novotney have reported no biomedical financial interests or potential conflicts of interest.


© 2024  American Academy of Child and Adolescent Psychiatry. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 64 - N° 4

P. 447-462 - avril 2025 Retour au numéro
Article précédent Article précédent
  • Systematic Review and Meta-Analysis: Multisystemic Therapy and Functional Family Therapy Targeting Antisocial Behavior in Adolescence
  • Hugh Hunkin, Catia G. Malvaso, Catherine R. Chittleborough, Angela Gialamas, Alicia Montgomerie, Kathleen Falster, John Lynch, Rhiannon M. Pilkington
| Article suivant Article suivant
  • Associations Between Neighborhood Resources and Youths’ Response to Reward Omission in a Task Modeling Negatively Biased Environments
  • Berron Brown, Lynn T. Nguyen, Isaac Morales, Elise M. Cardinale, Wan-Ling Tseng, Cameron C. McKay, Katharina Kircanski, Melissa A. Brotman, Daniel S. Pine, Ellen Leibenluft, Julia O. Linke

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Elsevier s'engage à rendre ses eBooks accessibles et à se conformer aux lois applicables. Compte tenu de notre vaste bibliothèque de titres, il existe des cas où rendre un livre électronique entièrement accessible présente des défis uniques et l'inclusion de fonctionnalités complètes pourrait transformer sa nature au point de ne plus servir son objectif principal ou d'entraîner un fardeau disproportionné pour l'éditeur. Par conséquent, l'accessibilité de cet eBook peut être limitée. Voir plus

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2026 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.